Cargando…

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad-Roy, Chadi M., Morris, Sinead E., Metcalf, C. Jessica E., Mina, Michael J., Baker, Rachel E., Farrar, Jeremy, Holmes, Edward C., Pybus, Oliver G., Graham, Andrea L., Levin, Simon A., Grenfell, Bryan T., Wagner, Caroline E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128287/
https://www.ncbi.nlm.nih.gov/pubmed/33688062
http://dx.doi.org/10.1126/science.abg8663
_version_ 1783694092415270912
author Saad-Roy, Chadi M.
Morris, Sinead E.
Metcalf, C. Jessica E.
Mina, Michael J.
Baker, Rachel E.
Farrar, Jeremy
Holmes, Edward C.
Pybus, Oliver G.
Graham, Andrea L.
Levin, Simon A.
Grenfell, Bryan T.
Wagner, Caroline E.
author_facet Saad-Roy, Chadi M.
Morris, Sinead E.
Metcalf, C. Jessica E.
Mina, Michael J.
Baker, Rachel E.
Farrar, Jeremy
Holmes, Edward C.
Pybus, Oliver G.
Graham, Andrea L.
Levin, Simon A.
Grenfell, Bryan T.
Wagner, Caroline E.
author_sort Saad-Roy, Chadi M.
collection PubMed
description Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection dynamics and how it will affect prospects for the evolution of viral immune escape via a buildup of partially immune individuals. Both hinge on the robustness of the immune response elicited by a single dose as compared with natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short term, focusing on one dose generally decreases infections, but that longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose and to ramp up vaccination efforts globally.
format Online
Article
Text
id pubmed-8128287
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-81282872021-05-18 Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes Saad-Roy, Chadi M. Morris, Sinead E. Metcalf, C. Jessica E. Mina, Michael J. Baker, Rachel E. Farrar, Jeremy Holmes, Edward C. Pybus, Oliver G. Graham, Andrea L. Levin, Simon A. Grenfell, Bryan T. Wagner, Caroline E. Science Research Articles Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection dynamics and how it will affect prospects for the evolution of viral immune escape via a buildup of partially immune individuals. Both hinge on the robustness of the immune response elicited by a single dose as compared with natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short term, focusing on one dose generally decreases infections, but that longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose and to ramp up vaccination efforts globally. American Association for the Advancement of Science 2021-04-23 2021-03-09 /pmc/articles/PMC8128287/ /pubmed/33688062 http://dx.doi.org/10.1126/science.abg8663 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Saad-Roy, Chadi M.
Morris, Sinead E.
Metcalf, C. Jessica E.
Mina, Michael J.
Baker, Rachel E.
Farrar, Jeremy
Holmes, Edward C.
Pybus, Oliver G.
Graham, Andrea L.
Levin, Simon A.
Grenfell, Bryan T.
Wagner, Caroline E.
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
title Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
title_full Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
title_fullStr Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
title_full_unstemmed Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
title_short Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
title_sort epidemiological and evolutionary considerations of sars-cov-2 vaccine dosing regimes
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128287/
https://www.ncbi.nlm.nih.gov/pubmed/33688062
http://dx.doi.org/10.1126/science.abg8663
work_keys_str_mv AT saadroychadim epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT morrissineade epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT metcalfcjessicae epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT minamichaelj epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT bakerrachele epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT farrarjeremy epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT holmesedwardc epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT pybusoliverg epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT grahamandreal epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT levinsimona epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT grenfellbryant epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes
AT wagnercarolinee epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes